Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.5K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.5K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.2K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.2K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

122
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
122
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

567
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
567

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating ACE2 levels and ACE I/D polymorphism in severe aortic stenosis.

Scientific reports·2026
Same author

Asymptomatic WPW Pattern Detected by School ECG Screening: Prevalence, Phenotype, and Automated Interpretation Errors.

Biomedicines·2026
Same author

Radiofrequency, Cryoablation, and Pulsed Field Ablation for Atrial Fibrillation: Mechanisms, Preclinical Evidence, and Clinical Outcomes.

Biomedicines·2026
Same author

Mechanical Dispersion in Dilated and Non-Dilated Left Ventricular Cardiomyopathy: A New Frontier in Arrhythmic Risk Prediction.

Journal of clinical medicine·2026
Same author

Biomarkers for Screening and Diagnosis of Heart Failure in Cardiovascular-Kidney-Metabolic Syndrome: A Narrative Review.

International journal of molecular sciences·2026
Same author

Exploratory Retrospective Assessment of Patients with Psoriasis Receiving Biological Therapy.

Medicina (Kaunas, Lithuania)·2026

Related Experiment Video

Updated: Apr 10, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.8K

Renin Genetic Polymorphism in Heart Failure Patients.

Dana Pop, Adela-Viviana Sitar-Tăut, Lucia Procopciuc

    Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne
    |June 17, 2015
    PubMed
    Summary
    This summary is machine-generated.

    This study found that A/G renin genetic polymorphism does not appear to play a role in the development of heart failure (HF). Researchers analyzed renin gene variations in HF patients and control groups, observing no significant association with HF pathogenesis.

    More Related Videos

    Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model
    10:18

    Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model

    Published on: June 29, 2014

    17.7K
    Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
    12:03

    Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

    Published on: June 7, 2016

    18.6K

    Related Experiment Videos

    Last Updated: Apr 10, 2026

    A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
    08:21

    A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

    Published on: October 26, 2020

    5.8K
    Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model
    10:18

    Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model

    Published on: June 29, 2014

    17.7K
    Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
    12:03

    Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

    Published on: June 7, 2016

    18.6K

    Area of Science:

    • Cardiovascular Genetics
    • Molecular Cardiology
    • Hypertension Research

    Background:

    • The renin-angiotensin-aldosterone system (RAAS) is crucial in regulating blood pressure and fluid balance.
    • Genetic variations within the RAAS, including renin, are implicated in the pathogenesis of cardiovascular diseases such as hypertension (HTN), ischemic heart disease (IHD), and heart failure (HF).

    Purpose of the Study:

    • To investigate the association between A/G renin genetic polymorphism and the occurrence of heart failure (HF).
    • To analyze the prevalence of specific renin gene polymorphisms in patients with established HF compared to a control group.

    Main Methods:

    • A cohort of 83 subjects was studied, including 43 patients diagnosed with heart failure (NYHA class III-IV) and 40 healthy individuals as a control group.
    • Renin polymorphism was analyzed using the polymerase chain reaction (PCR) amplification method.
    • Biomarkers such as NT-proBNP and cardiovascular risk factors (lipids, obesity, diabetes) were assessed in all participants.

    Main Results:

    • Ischemic heart disease (IHD) was the primary etiology of heart failure in 60.46% of the patient cohort.
    • The A/G renin genetic polymorphism, considered to have pathogenic potential, was present in 60.46% of heart failure patients (4.65% homozygote, 55.81% heterozygote).
    • In contrast, the heterozygote form of this polymorphism was found in only 37.5% of control subjects. Pathogenic mutations were also noted in hypertensive patients (38.46%), and those with obesity/overweight (55.88%) and diabetes (22.22%).

    Conclusions:

    • The study concluded that A/G renin polymorphisms do not appear to be significantly involved in the pathogenesis of heart failure (HF).
    • While the A/G renin polymorphism was more prevalent in HF patients than controls, this association did not meet statistical significance for a causal role in HF development.